mercredi 27 novembre 2019

Onco Actu du 27 novembre 2019


1. BIOLOGIE



Turning Key Metabolic Process Back On Could Make Sarcoma More Susceptible to Treatment [Penn Medicine]











Intestinal Stem Cell Genes May Link Dietary Fat and Colon Cancer [Rutgers]











Science Surgery: ‘Why do some cancers metastasise, but others don’t?’ [Cancer Research UK]











Splicing factor to blame in triple negative breast cancer [EurekAlert!]











A novel pathway to target colorectal cancer [Medical University of South Carolina]











1.1 BIOLOGIE - GÉNOME



Understanding why men get more cancer than women [Peter MacCallum Cancer Center]










3.1.1 PRÉVENTION - TABAC - E-CIGS



New CDC report offers a possible clue about why vaping illnesses sprang up in 2019 [STAT]











Why E-Cigarette Flavor Bans are Misguided: The Flavor's Not the Problem, It's the Nicotine Salts [The Rest of the Story]










Characteristics of E-cigarette, or Vaping, Products Used by Patients with Associated Lung Injury and Products Seized by Law Enforcement — Minnesota, 2018 and 2019 [CDC]











More Evidence that Vitamin E Acetate Oil, Not E-Cigarettes, Is the Cause of the Respiratory Disease Outbreak [The Rest of the Story]











How safe is vaping? New human studies assess chronic harm to heart and lungs [Science]











4.9 DÉP., DIAG. & PRONO. - SEIN



Biennial Mammography Screening Yields More Advanced-Stage Cancers [PR Newswire]











5.12.5 IMMUNOTHÉRAPIES - PHARMA



Roche takes aim at Bayer's liver cancer share with big Tecentriq-Avastin win [Fierce Pharma]











5.12.5.1 IMMUNOTHÉRAPIES - BIOTECH



Another cancer vaccine play out of Geneva shoots for 'hard endpoint' in PhII head and neck cancer test [EndPoints]











5.12.6 IMMUNOTHÉRAPIES - AMM



Merck’s KEYTRUDA® (pembrolizumab) Now Approved in China for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy [Merck]











5.12.7 IMMUNOTHÉRAPIES - VACCINS



UK and China research team take first steps towards a vaccine for pancreatic cancer [Queen Mary University of London]











5.12.8 IMMUNOTHÉRAPIES - ECONOMIE



Bladder cancer treatment rejected for routine use on NHS in England [Cancer Research UK]











5.2.3 PHARMA - ÉCONOMIE



There’s one endpoint that the booming biopharma industry has failed at miserably: financial toxicity [EndPoints]










5.3 TRAITEMENTS - FDA, EMA, NICE...



FDA’s Office of Hematology and Oncology Products Reorganizes [Cancer Research Catalyst]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



FDA Approves Acalabrutinib for CLL and SLL [ESMO]











5.4 TRAITEMENTS - ECONOMIE



Payer Funding Of Interventional Pharmacoeconomic Studies: A New Paradigm [Health Affairs]










5.6 ESMO



Korea Drug Stock Soars After Plaudit But There Was No Award [Bloomberg]











6.3 ASSOCIATIONS/FONDATIONS



The Loneliest Cancer [Sarcoma UK]











6.7 DMP, BIG DATA & APPLIS



NHS has ‘big tech’ patient data analysis fears [PharmaTimes]